Characterization and function of the human macrophage dopaminergic system: Implications for CNS disease and drug abuse

Journal of Neuroinflammation

Volumn 9, Issue , 2012, Pages

  Gaskill, Peter J ^a   Carvallo, Loreto ^a   Eugenin, Eliseo A ^a,b   Berman, Joan W ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

Aromatic amino acid decarboxylase; Cytokine; Dopamine; Dopamine transporter; Drug abuse; Monocyte derived macrophage; Neuroinflammation dopamine receptor; Tyrosine hydroxylase

Indexed keywords

EID: 84865053439     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-9-203     Document Type: Article

References (83)

1. Kimmel HL, Ginsburg BC, Howell LL. Changes in extracellular dopamine during cocaineself-administration in squirrel monkeys. Synapse 2005, 56(3):129-134. 10.1002/syn.20135, 15765537.
2. Desai RI, Paronis CA, Martin J, Desai R, Bergman J. Monoaminergic psychomotorstimulants: discriminative stimulus effects and dopamine efflux. J Pharmacol Exp Ther 2010, 333(3):834-843. 10.1124/jpet.110.165746, 2879939, 20190012.
3. Garris PA, Ciolkowski EL, Pastore P, Wightman RM. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 1994, 14:6084-6093.
4. Gonon FG, Buda MJ. Regulation of dopamine release by impulse flow and byautoreceptors as studied by in vivo voltammetry in the rat striatum. Neuroscience 1985, 14:765-774. 10.1016/0306-4522(85)90141-1, 2986044.
5. Sulzer D, Zhang H, Benoit-Marand M, Gonon F. Regulation of Extracellular Dopamine: Release and Reuptake. The Handbook of Basal Ganglia Structure and Function. First edn 2010, 297-319. Boston, MA: Academic Press, Steiner HT, Kuei .
6. D'Aquila PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000, 405:365-373. 10.1016/S0014-2999(00)00566-5, 11033341.
7. Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. J Pharmacol Exp Ther 1975, 195:453-464.
8. Ng KY, Chase TN, Colburn RW, Kopin IJ. L-Dopa-induced release of cerebral monoamines. Science 1970, 170(3953):76-77. 10.1126/science.170.3953.76, 5452893.
9. Volkow ND, Wang GJ, Fowler JS, Thanos PP, Logan J, Gatley SJ, Gifford A, Ding YS, Wong C, Pappas N. Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse 2002, 46:79-82. 10.1002/syn.10137, 12211085.
10. Zhang L, Zhou FM, Dani JA. Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release. Mol Pharmacol 2004, 66:538-544. 10.1124/mol.104.000299, 15322245.
11. Izzo E, Sanna PP, Koob GF. Impairment of dopaminergic system function after chronictreatment with corticotropin-releasing factor. Pharmacol Biochem Behav 2005, 81:701-708. 10.1016/j.pbb.2005.04.017, 16005056.
12. Maia TV, Frank MJ. From reinforcement learning models to psychiatric and neurological disorders. Nat Neurosci 2011, 14:154-162. 10.1038/nn.2723, 21270784.
13. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2008, 455(7215):894-902. 10.1038/nature07455, 2721780, 18923511.
14. Scheller C, Arendt G, Nolting T, Antke C, Sopper S, Maschke M, Obermann M, Angerer A, Husstedt IW, Meisner F, et al. Increased dopaminergic neurotransmission in therapy-naiveasymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses. J Neural Transm 2010, 117:699-705. 10.1007/s00702-010-0415-6, 20454983.
15. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. Presynaptic dopaminergicdysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Arch Gen Psychiatry 2004, 61:134-142. 10.1001/archpsyc.61.2.134, 14757589.
16. Mackay AV, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I. Synder SH:Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 1982, 39:991-997. 10.1001/archpsyc.1982.04290090001001, 7115016.
17. Cosentino M, Fietta AM, Ferrari M, Rasini E, Bombelli R, Carcano E, Saporiti F, Meloni F, Marino F, Lecchini S. Human CD4 + CD25+ regulatory T cells selectively express tyrosinehydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 2007, 109:632-642. 10.1182/blood-2006-01-028423, 16985181.
18. Tarazona R, Gonzalez-Garcia A, Zamzami N, Marchetti P, Frechin N, Gonzalo JA, Ruiz-Gayo M, van Rooijen N, Martinez C, Kroemer G. Chlorpromazine amplifies macrophage-dependent IL-10 production in vivo. J Immunol 1995, 154:861-870.
19. Farber K, Pannasch U, Kettenmann H. Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol Cell Neurosci 2005, 29:128-138. 10.1016/j.mcn.2005.01.003, 15866053.
20. Besser MJ, Ganor Y, Levite M. Dopamine by itself activates either D2, D3 or D1/D5dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both. J Neuroimmunol 2005, 169:161-171. 10.1016/j.jneuroim.2005.07.013, 16150496.
21. Levite M, Chowers Y, Ganor Y, Besser M, Hershkovits R, Cahalon L. Dopamine interactsdirectly with its D3 and D2 receptors on normal human T cells, and activates beta1integrin function. Eur J Immunol 2001, 31:3504-3512. 10.1002/1521-4141(200112)31:12<3504::AID-IMMU3504>3.0.CO;2-F, 11745370.
22. Hasko G, Szabo C, Nemeth ZH, Deitch EA. Dopamine suppresses IL-12 p40 production bylipopolysaccharide-stimulated macrophages via a beta-adrenoceptor-mediatedmechanism. J Neuroimmunol 2002, 122:34-39. 10.1016/S0165-5728(01)00459-3, 11777541.
23. Torres KC, Antonelli LR, Souza AL, Teixeira MM, Dutra WO, Gollob KJ. Norepinephrine, dopamine and dexamethasone modulate discrete leukocyte subpopulations andcytokine profiles from human PBMC. J Neuroimmunol 2005, 166:144-157. 10.1016/j.jneuroim.2005.06.006, 16026859.
24. Watanabe Y, Nakayama T, Nagakubo D, Hieshima K, Jin Z, Katou F, Hashimoto K, Yoshie O. Dopamine selectively induces migration and homing of naive CD8+ T cells via dopaminereceptor D3. J Immunol 2006, 176:848-856.
25. Rivest S. Regulation of innate immune responses in the brain. Nat Rev Immunol 2009, 9:429-439. 10.1038/nri2565, 19461673.
26. Minagar A, Shapshak P, Fujimura R, Ownby R, Heyes M, Eisdorfer C. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologicdisorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 2002, 202:13-23. 10.1016/S0022-510X(02)00207-1, 12220687.
27. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69. 10.1038/nrn2038, 17180163.
28. Molinoff PB, Axelrod J. Biochemistry of catecholamines. Annu Rev Biochem 1971, 40:465-500.
29. Daubner SC, Le T, Wang S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 2011, 508:1-12. 10.1016/j.abb.2010.12.017, 3065393, 21176768.
30. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev 1998, 78:189-25.
31. Horn AS. Dopamine uptake: a review of progress in the last decade. Prog Neurobiol 1990, 34:387-400. 10.1016/0301-0082(90)90033-D, 2192393.
32. Mignini F, Tomassoni D, Traini E, Amenta F. Dopamine, vesicular transporters anddopamine receptor expression and localization in rat thymus and spleen. J Neuroimmunol 2009, 206:5-13. 10.1016/j.jneuroim.2008.09.018, 19012970.
33. Halbach Ov B, Dermietzel R. Neurotransmitters and neuromodulators : handbook of receptors and biological effects, 2nd. rev. and enl. ed edn 2006, Weinheim: Wiley-VCH.
34. Kopin IJ. Monoamine oxidase and catecholamine metabolism. J Neural Transm Suppl 1994, 41:57-67.
35. Weihe E, Eiden LE. Chemical neuroanatomy of the vesicular amine transporters. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2000, 14(15):2435-2449.
36. McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, Bowen-Jones D, Moots RJ. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol 2002, 132:34-40. 10.1016/S0165-5728(02)00280-1, 12417431.
37. Alberio T, Anchieri C, Piacentini L, Gentile G, Simmaco M, Biasin M, Fasano M. Proteomic characterization of Jurkat T leukemic cells after dopamine stimulation: A model of circulating dopamine-sensitive cells. Biochimie 2011, 93:892-898. 10.1016/j.biochi.2011.01.015, 21300132.
38. Kokkinou I, Nikolouzou E, Hatzimanolis A, Fragoulis EG, Vassilacopoulou D. Expression of enzymatically active L-DOPA decarboxylase in human peripheral leukocytes. Blood Cells Mol Dis 2009, 42:92-98. 10.1016/j.bcmd.2008.10.010, 19041269.
39. Amenta F, Bronzetti E, Cantalamessa F, El-Assouad D, Felici L, Ricci A, Tayebati SK. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J Neuroimmunol 2001, 117:133-142. 10.1016/S0165-5728(01)00317-4, 11431013.
40. Cosentino M, Marino F, Bombelli R, Ferrari M, Lecchini S, Frigo G. Endogenouscatecholamine synthesis, metabolism, storage and uptake in human neutrophils. Life Sci 1999, 64:975-981. 10.1016/S0024-3205(99)00023-5, 10201646.
41. Kipnis J, Cardon M, Avidan H, Lewitus GM, Mordechay S, Rolls A, Shani Y, Schwartz M. Dopamine, through the extracellular signal-regulated kinase pathway, downregulatesCD4 + CD25+ regulatory T-cell activity: implications for neurodegeneration. The Journal of neuroscience : the official journal of the Society for Neuroscience 2004, 24:6133-6143.
42. Sarkar C, Das S, Chakroborty D, Chowdhury UR, Basu B, Dasgupta PS, Basu S. CuttingEdge: Stimulation of dopamine D4 receptors induce T cell quiescence by up-regulatingKruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. J Immunol 2006, 177:7525-7529.
43. Ghosh MC, Mondal AC, Basu S, Banerjee S, Majumder J, Bhattacharya D, Dasgupta PS. Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells. Int Immunopharmacol 2003, 3:1019-1026. 10.1016/S1567-5769(03)00100-0, 12810359.
44. Sookhai S, Wang JH, McCourt M, O'Connell D, Redmond HP. Dopamine induces neutrophilapoptosis through a dopamine D-1 receptor-independent mechanism. Surgery 1999, 126:314-322. 10.1016/S0039-6060(99)70171-6, 10455900.
45. Sookhai S, Wang JH, Winter D, Power C, Kirwan W, Redmond HP. Dopamine attenuates thechemoattractant effect of interleukin-8: a novel role in the systemic inflammatoryresponse syndrome. Shock 2000, 14:295-299. 10.1097/00024382-200014030-00009, 11028546.
46. Anlauf M, Schafer MK, Schwark T, von Wurmb-Schwark N, Brand V, Sipos B, Horny HP, Parwaresch R, Hartschuh W, Eiden LE, et al. Vesicular monoamine transporter 2 (VMAT2) expression in hematopoietic cells and in patients with systemic mastocytosis. J Histochem Cytochem 2006, 54:201-213. 10.1369/jhc.5A6739.2005, 16116033.
47. Kokkinou I, Fragoulis EG, Vassilacopoulou D. The U937 macrophage cell line expressesenzymatically active L-Dopa decarboxylase. J Neuroimmunol 2009, 216:51-58. 10.1016/j.jneuroim.2009.09.001, 19800137.
48. Capellino S, Cosentino M, Wolff C, Schmidt M, Grifka J, Straub RH. Catecholamine-producing cells in the synovial tissue during arthritis: modulation of sympatheticneurotransmitters as new therapeutic target. Ann Rheum Dis 2010, 69:1853. 10.1136/ard.2009.119701, 20498218.
49. Gaskill PJ, Calderon TM, Luers AJ, Eugenin EA, Javitch JA, Berman JW. Human immunodeficiency virus (HIV) infection of human macrophages is increased bydopamine: a bridge between HIV-associated neurologic disorders and drug abuse. Am J Pathol 2009, 175:1148-1159. 10.2353/ajpath.2009.081067, 2731133, 19661443.
50. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist progammers. >In Bioinformatics Methods and Protocols: Methods in Molecular Biology 2000, 365-386. Humana Press, Krawetz S, Misener S, Totowa NJ, Source code available at http://fokker.wi.mit.edu/primer3.
51. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990, 215:403-410.
52. Mallat M, Chamak B. Brain macrophages: neurotoxic or neurotrophic effector cells?. J Leukoc Biol 1994, 56:416-422.
53. Cragg SJ, Rice ME. DAncing past the DAT at a DA synapse. Trends Neurosci 2004, 27:270-277. 10.1016/j.tins.2004.03.011, 15111009.
54. Venton BJ, Zhang H, Garris PA, Phillips PE, Sulzer D, Wightman RM. Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasicfiring. J Neurochem 2003, 87:1284-1295. 10.1046/j.1471-4159.2003.02109.x, 14622108.
55. Schiffer WK, Azmoodeh M, Gerasimov M, Volkow ND, Fowler JS, Dewey SL. Selegilinepotentiates cocaine-induced increases in rodent nucleus accumbens dopamine. Synapse 2003, 48:35-38. 10.1002/syn.10183, 12557270.
56. Phillips PE, Stuber GD, Heien ML, Wightman RM, Carelli RM. Subsecond dopamine release promotes cocaine seeking. Nature 2003, 422(6932):614-618. 10.1038/nature01476, 12687000.
57. Hermans A, Keithley RB, Kita JM, Sombers LA, Wightman RM. Dopamine detection withfast-scan cyclic voltammetry used with analog background subtraction. Anal Chem 2008, 80:4040-4048. 10.1021/ac800108j, 18433146.
58. Zachek MK, Takmakov P, Park J, Wightman RM, McCarty GS. Simultaneous monitoring of dopamine concentration at spatially different brain locations in vivo. Biosens Bioelectron 2010, 25:1179-1185. 10.1016/j.bios.2009.10.008, 2818289, 19896822.
59. Ilani T, Ben-Shachar D, Strous RD, Mazor M, Sheinkman A, Kotler M, Fuchs S. A peripheralmarker for schizophrenia: Increased levels of D3 dopamine receptor mRNA in bloodlymphocytes. Proc Natl Acad Sci U S A 2001, 98:625-628. 10.1073/pnas.98.2.625, 14638, 11149951.
60. Liang H, Wang X, Chen H, Song L, Ye L, Wang SH, Wang YJ, Zhou L, Ho WZ. Methamphetamine enhances HIV infection of macrophages. Am J Pathol 2008, 172:1617-1624. 10.2353/ajpath.2008.070971, 2408421,2408421, 18458095.
61. Rudd ML, Nicolas AN, Brown BL, Fischer-Stenger K, Stewart JK. Peritoneal macrophages express the serotonin transporter. J Neuroimmunol 2005, 159:113-118. 10.1016/j.jneuroim.2004.10.013, 15652409.
62. Marazziti D, Baroni S, Catena Dell'Osso M, Masala I, Fabbrini L, Betti L, Giannaccini G, Dell'osso B, Lucacchini A. Presence and characterization of the dopamine transporter inhuman resting lymphocytes. Neurochem Res 2008, 33:1011-1016. 10.1007/s11064-007-9541-4, 18038207.
63. Caronti B, Antonini G, Calderaro C, Ruggieri S, Palladini G, Pontieri FE, Colosimo C. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson'sdisease. J Neural Transm 2001, 108:803-807. 10.1007/s007020170030, 11515746.
64. Meredith EJ, Holder MJ, Rosen A, Lee AD, Dyer MJ, Barnes NM, Gordon J. Dopaminetargets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin's lymphoma. Proc Natl Acad Sci U S A 2006, 103:13485-13490. 10.1073/pnas.0605993103, 1569189, 16938864.
65. Brown SW, Meyers RT, Brennan KM, Rumble JM, Narasimhachari N, Perozzi EF, Ryan JJ, Stewart JK, Fischer-Stenger K. Catecholamines in a macrophage cell line. J Neuroimmunol 2003, 135:47-55. 10.1016/S0165-5728(02)00435-6, 12576223.
66. Flierl MA, Rittirsch D, Nadeau BA, Chen AJ, Sarma JV, Zetoune FS, McGuire SR, List RP, Day DE, Hoesel LM, et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 2007, 449(7163):721-725. 10.1038/nature06185, 17914358.
67. Cosentino M, Bombelli R, Ferrari M, Marino F, Rasini E, Maestroni GJ, Conti A, Boveri M, Lecchini S, Frigo G. HPLC-ED measurement of endogenous catecholamines in humanimmune cells and hematopoietic cell lines. Life Sci 2000, 68:283-295. 10.1016/S0024-3205(00)00937-1, 11191644.
68. Ilani T, Strous RD, Fuchs S. Dopaminergic regulation of immune cells via D3 dopaminereceptor: a pathway mediated by activated T cells. The FASEB journal : official publicationof the Federation of American Societies for Experimental Biology 2004, 18:1600.
69. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, et al. Microbial translocation is a cause of systemic immuneactivation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
70. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, et al. Microbial translocation is associated with increased monocyteactivation and dementia in AIDS patients. PLoS One 2008, 3:e2516. 10.1371/journal.pone.0002516, 2424175, 18575590.
71. Gouwy M, Struyf S, Noppen S, Schutyser E, Springael JY, Parmentier M, Proost P, VanDamme J. Synergy between coproduced CC and CXC chemokines in monocytechemotaxis through receptor-mediated events. Mol Pharmacol 2008, 74:485-495. 10.1124/mol.108.045146, 18469140.
72. Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, Berman JW. CCL2/monocytechemoattractant protein-1 mediates enhanced transmigration of humanimmunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: apotential mechanism of HIV-CNS invasion and NeuroAIDS. The Journal of neuroscience : the official journal of the Society for Neuroscience 2006, 26:1098-1106.
73. Kossmann T, Stahel PF, Lenzlinger PM, Redl H, Dubs RW, Trentz O, Schlag G, Morganti-Kossmann MC. Interleukin-8 released into the cerebrospinal fluid after brain injury isassociated with blood-brain barrier dysfunction and nerve growth factor production. Journal of cerebral blood flow and metabolism : official journal of the International Society ofCerebral Blood Flow and Metabolism 1997, 17(3):280-289.
74. McManus CM, Liu JS, Hahn MT, Hua LL, Brosnan CF, Berman JW, Lee SC. Differential induction of chemokines in human microglia by type I and II interferons. Glia 2000, 29:273-280. 10.1002/(SICI)1098-1136(20000201)29:3<273::AID-GLIA8>3.0.CO;2-9, 10642753.
75. Cacquevel M, Lebeurrier N, Cheenne S, Vivien D. Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets 2004, 5:529-534. 10.2174/1389450043345308, 15270199.
76. Xiong H, Boyle J, Winkelbauer M, Gorantla S, Zheng J, Ghorpade A, Persidsky Y, Carlson KA, Gendelman HE. Inhibition of long-term potentiation by interleukin-8: implications forhuman immunodeficiency virus-1-associated dementia. J Neurosci Res 2003, 71:600-607. 10.1002/jnr.10503, 12548717.
77. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG. Does neuroinflammation fan the flame in neurodegenerative diseases?. Mol Neurodegener 2009, 4:47. 10.1186/1750-1326-4-47, 2784760, 19917131.
78. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novoParkinson's disease patients. Neurosci Lett 1995, 202:17-20. 10.1016/0304-3940(95)12192-7, 8787820.
79. McGuire SO, Ling ZD, Lipton JW, Sortwell CE, Collier TJ, Carvey PM. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp Neurol 2001, 169:219-230. 10.1006/exnr.2001.7688, 11358437.
80. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, Tansey KE, Tansey MG. Blocking soluble tumor necrosis factor signaling with dominant-negativetumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. The Journal of neuroscience : the official journal of the Society for Neuroscience 2006, 26:9365-9375.
81. Eugenin EA, Berman JW. Chemokine-dependent mechanisms of leukocyte traffickingacross a model of the blood-brain barrier. Methods 2003, 29:351-361. 10.1016/S1046-2023(02)00359-6, 12725802.
82. Knoblach SM, Faden AI. Interleukin-10 improves outcome and alters proinflammatorycytokine expression after experimental traumatic brain injury. Exp Neurol 1998, 153:143-151. 10.1006/exnr.1998.6877, 9743576.
83. Ziebell JM, Morganti-Kossmann MC. Involvement of pro- and anti-inflammatory cytokinesand chemokines in the pathophysiology of traumatic brain injury. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2010, 7:22-30.